Genentech Says FDA Approves Actemra Arthritis Drug

By: Associated Press Email
By: Associated Press Email

SOUTH SAN FRANCISCO, Calif. (AP) - Biotechnology company Genentech Inc. says the U.S. Food and Drug Administration has approved its new drug to treat rheumatoid arthritis.

The approval of the drug, Actemra, "marks a major step forward" in the treatment of the disease, Hal Barron, chief medical officer for Genentech and its parent company, the Roche Group, said in a statement. Development of the drug involved five Phase 3 clinical studies and more than 4,000 participants in 41 countries, Genentech said.

Actemra works by blocking the effect of a certain protein associated with inflammation. But because Actemra acts to suppress the immune system, it can also have serious side effects, including severe infections, liver abnormalities and damage to digestive organs.

Rheumatoid arthritis affects about 1.3 million people in the U.S., according to the Arthritis Foundation.

The drug was co-developed with Japan's Chugai Pharmaceutical Co. and has been approved for use in Japan since 2005. It is also approved in the European Union, India, Brazil, Switzerland and Australia.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KOLO-TV 4850 Ampere Drive Reno, NV 89502
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 81072312